Objective The global aim of RAPSODI is : · to develop a human vaccine candidate against most or all Leishmania species that cause the most severe leishmaniasis in the world. An unique vaccinal solution will thus be provided to protect against the various clinical phenotypes (namely visceral, cutaneous and mucocutaneaous leishmaniasis, VL, CL and ML respectively). · to establish all the associated procedures required for the subsequent clinical trials, such as the selection of the appropriate patients and assessment of vaccine efficiency. For that purpose, an international consortium constituted of countries from endemic areas (India, Peru, Tunisia, Spain and France) and embracing multi-disciplinary approaches has been set-up. Based on successful results on VL dogs, the best VL animal model to date, RAPSODI will propose a second generation human-compatible vaccine candidate and confirm its activity in pre-clinical studies. As the chosen antigen is common to most, if not all, Leishmania species, an ambitious universal immunoprotective response is being sought. RAPSODI will also address the question of population selection in order to ascertain relevant and meaningful clinical trials and vaccination campaigns. Indeed, resistant individuals, when involved in either vaccinated or placebo groups, represent important bias to the analysis of the results. RAPSODI will investigate further the parasitological, immunological and genetic features of such clinical status, and will subsequently apply the generated knowledge to the development of assays and field tests, which represent stand-alone results. The package (vaccine candidate + diagnostic/prognostic tools) proposed by RAPSODI represents a global solution, and as such is believed to have a real impact on the worldwide leishmaniasis problem. Fields of science agricultural sciencesanimal and dairy sciencedomestic animalsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Keywords Leishmaniasis diagnosis efficacy follow-up leishmania pre-clinical trials resistance features vaccination vaccine vaccine candidate Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH-2007-2.3.4-2 - Development of a Leishmania vaccine Call for proposal FP7-HEALTH-2007-B See other projects for this call Funding Scheme CP-SICA - Collaborative project for specific cooperation actions dedicated to international cooperation partner countries (SICA) Coordinator VIRBAC SA EU contribution € 565 024,60 Address RUE 13EME LID 06511 CARROS France See on map Region Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Alpes-Maritimes Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Cherifa Hemadou (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (8) Sort alphabetically Sort by EU Contribution Expand all Collapse all INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT France EU contribution € 404 093,00 Address BOULEVARD DE DUNKERQUE 44 CS 90009 13572 Marseille See on map Region Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône Activity type Research Organisations Administrative Contact Ariel Crozon (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data INSTITUTO DE SALUD CARLOS III Spain EU contribution € 554 300,80 Address MONFORTE DE LEMOS 5 28029 Madrid See on map Region Comunidad de Madrid Comunidad de Madrid Madrid Activity type Research Organisations Administrative Contact Inmaculada Pastor (Ms.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data INDIAN COUNCIL OF MEDICAL RESEARCHSOCIETY India EU contribution € 330 840,00 Address ANSARI NAGAR 110029 New Delhi See on map Activity type Research Organisations Administrative Contact Sunita Saxena (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data UNIVERSIDAD PERUANA CAYETANO HEREDIA Peru EU contribution € 444 351,70 Address HONORIO DELGADO 430 31 Lima See on map Activity type Higher or Secondary Education Establishments Administrative Contact Oscar Situ (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data INSTITUT PASTEUR DE TUNIS Tunisia EU contribution € 300 175,70 Address Place Pasteur 13 1002 Tunis See on map Activity type Research Organisations Administrative Contact Faycal Chaabane (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data AYMING France EU contribution € 90 680,00 Address RUE CHAPTAL 114 92300 Levallois-Perret See on map Region Ile-de-France Ile-de-France Hauts-de-Seine Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Frederic Peyrane (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data INSTIMED Participation ended France EU contribution € 4 500,00 Address Rue Joseph Cugnot, Levée de Rochepinard 37702 Saint Pierre des Corps See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Jean-Michel Bousquet (Mr.) Links Contact the organisation Opens in new window Total cost No data SYNCROSOME SAS France EU contribution € 43 183,20 Address AVENUE DE LUMINY - LUMINY BIOTECH CP 908 163 13288 MARSEILLE See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Richard Mitry (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data